These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 23400594)

  • 1. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.
    Casetti L; Martin-Lannerée S; Najjar I; Plo I; Augé S; Roy L; Chomel JC; Lauret E; Turhan AG; Dusanter-Fourt I
    Cancer Res; 2013 Apr; 73(7):2052-8. PubMed ID: 23400594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
    Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
    Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.
    Kaymaz BT; Günel NS; Ceyhan M; Çetintaş VB; Özel B; Yandım MK; Kıpçak S; Aktan Ç; Gökbulut AA; Baran Y; Can BK
    Tumour Biol; 2015 Sep; 36(10):7915-27. PubMed ID: 25953263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
    Corbin AS; O'Hare T; Gu Z; Kraft IL; Eiring AM; Khorashad JS; Pomicter AD; Zhang TY; Eide CA; Manley PW; Cortes JE; Druker BJ; Deininger MW
    Cancer Res; 2013 Sep; 73(18):5775-86. PubMed ID: 23887971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
    Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
    Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
    J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis.
    Kaymaz BT; Selvi N; Gündüz C; Aktan C; Dalmızrak A; Saydam G; Kosova B
    Ann Hematol; 2013 Jan; 92(2):151-62. PubMed ID: 23053176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
    Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
    Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity.
    Engler JR; Frede A; Saunders VA; Zannettino AC; Hughes TP; White DL
    Leukemia; 2010 Apr; 24(4):765-70. PubMed ID: 20147974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of TC-PTP (PTPN2) in modulating sensitivity to imatinib and interferon-α in CML cell line, KT-1 cells.
    Nishiyama-Fujita Y; Shimizu T; Sagawa M; Uchida H; Kizaki M
    Leuk Res; 2013 Sep; 37(9):1150-5. PubMed ID: 23759247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
    Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
    Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.
    Tobin LA; Robert C; Rapoport AP; Gojo I; Baer MR; Tomkinson AE; Rassool FV
    Oncogene; 2013 Apr; 32(14):1784-93. PubMed ID: 22641215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Getting to the stem of chronic myeloid leukaemia.
    Savona M; Talpaz M
    Nat Rev Cancer; 2008 May; 8(5):341-50. PubMed ID: 18385684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
    Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.